omeprazole and Pyrosis studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Research Excerpts

Excerpt	Relevance	Reference
"Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions."	9.69	Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023)
"Endoscopy-negative patients with heartburn who failed once daily PPIs were randomly allocated to receive 6 weeks treatment of fluoxetine, omeprazole, or placebo."	9.19	Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. ( Barzin, G; Emami, H; Farrokhi-Khajeh-Pasha, Y; Fotouhi, A; Hajifathalian, K; Mirbagheri, SA; Mirbagheri, SS; Ostovaneh, MR; Saeidi, B, 2014)
"To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux."	9.11	Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005)
"To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease."	9.11	Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005)
"To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)."	9.10	Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002)
" Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily."	9.10	Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003)
"Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease."	9.10	A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002)
"The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease."	9.09	Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000)
"05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo."	9.09	Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000)
"214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half the days over the past 6 months and during the 7- to 10-day pre-treatment period) were randomized to either lansoprazole 15 mg or lansoprazole 30 mg, or placebo o."	9.09	Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. ( Fisher, R; Greski-Rose, PA; Huang section sign, B; Kovacs, TO; Richter, JE, 1999)
"In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0."	9.09	Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999)
"Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom."	9.09	Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999)
"This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis."	9.09	Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001)
"Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality."	9.08	Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997)
"Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study."	9.08	Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997)
" This study assessed 20 mg omeprazole daily (OM20), 10 mg omeprazole daily (OM10), and 150 mg ranitidine (RAN) twice daily for symptom relief in gastro-oesophageal reflux disease (GORD)."	9.08	Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. ( Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL; Wilcock, C, 1997)
"Patients with heartburn, without endoscopic signs of oesophagitis, were randomized to double-blind treatment with omeprazole, 20 or 10 mg once daily, or placebo, for 4 weeks (n = 509)."	9.08	Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A, 1997)
"To examine dyspepsia symptom relief over 16 weeks and compare an omeprazole clinical management strategy with a commonly used combination of antacid-alginate followed by H2-antagonist."	9.08	The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. ( Evans, WM; Mason, I; Millar, LJ; Sheikh, RR; Taylor, MD; Todd, PL; Turbitt, ML, 1998)
" is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis."	9.08	Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998)
"To define the optimum doses of omeprazole appropriate for acute and long-term therapy of patients with gastro-oesophageal reflux disease, 24-h oesophageal pH was measured in 12 patients with symptomatic reflux and an abnormal 24-h oesophageal acid exposure time (greater than 6%) in a randomized, double-blind, four-way crossover study comparing the effects of omeprazole 10, 20, or 40 mg/day and placebo."	9.07	Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. ( Allen, ML; Bradstreet, TE; Cagliola, AJ; Humphries, TJ; Maton, PN; McIntosh, D; Robinson, M, 1991)
"To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis."	8.82	Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004)
"To report a case of chronic, persistent cough induced by omeprazole therapy."	7.72	Omeprazole-induced intractable cough. ( Delafosse, C; Howaizi, M, 2003)
"Heartburn was controlled on lansoprazole 30 mg/per day in 76."	7.72	Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003)
"A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician."	7.72	Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. ( Allgood, G; Allgood, L; Fendrick, AM; Grender, J; Peura, D; Schachtel, B; Shaw, M, 2004)
"To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease."	7.71	Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002)
"Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis."	7.69	Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997)
" These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms."	6.71	Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003)
"In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0."	6.71	Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004)
"Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions."	5.69	Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023)
"Patients who were referred to Veterans Affairs (VA) gastroenterology clinics for PPI-refractory heartburn received 20 mg of omeprazole twice daily for 2 weeks, and those with persistent heartburn underwent endoscopy, esophageal biopsy, esophageal manometry, and multichannel intraluminal impedance-pH monitoring."	5.30	Randomized Trial of Medical versus Surgical Treatment for Refractory Heartburn. ( Biswas, K; Castell, DO; Chan, BS; Chey, WD; Davis-Karim, A; Dunbar, KB; Fernando, RS; Gellad, ZF; Genta, RM; Ghaferi, AA; Huang, GD; Hunter, JG; Jackson, CS; Jones, KM; Kaz, AM; Kim, AW; Kim, T; Lagoo-Deenadayalan, S; Laine, L; Lee, R; Lieberman, D; Lo, WK; Mashimo, H; Melton, SD; Murthy, UK; Paski, SC; Pearl, JP; Pham, TH; Provenzale, D; Rubenstein, JH; Sanchez, VM; Serpi, T; Smith, BR; Souza, RF; Spechler, SJ; Tatum, RP; von Rosenvinge, EC; Wallen, JM; Warren, SR, 2019)
"Patients with persistent heartburn symptoms ≥ 3 times per week treated with omeprazole 20 mg daily were enrolled and randomized to commonly recommended dosing or continued suboptimal dosing of omeprazole."	5.30	Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial). ( Perzynski, AT; Votruba, M; Waghray, A; Waghray, N; Wolfe, MM, 2019)
"Zegerid (on demand immediate-release omeprazole and sodium bicarbonate combination therapy) has demonstrated earlier absorption and more rapid pH change compared with Losec (standard enteric coated omeprazole), suggesting more rapid clinical relief of heartburn."	5.20	Challenges of correlating pH change with relief of clinical symptoms in gastro esophageal reflux disease: a phase III, randomized study of Zegerid versus Losec. ( Gruss, HJ; Jones, D; Ng Kwet Shing, R; Reguła, J; Walker, D, 2015)
"Endoscopy-negative patients with heartburn who failed once daily PPIs were randomly allocated to receive 6 weeks treatment of fluoxetine, omeprazole, or placebo."	5.19	Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. ( Barzin, G; Emami, H; Farrokhi-Khajeh-Pasha, Y; Fotouhi, A; Hajifathalian, K; Mirbagheri, SA; Mirbagheri, SS; Ostovaneh, MR; Saeidi, B, 2014)
"Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis."	5.14	Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. ( Zheng, RN, 2009)
"Patients with heartburn for at least 2 days a week during the month before entry into the study and no endoscopic signs of a mucosal break (grade M or N according to Hoshihara's modification of the Los Angeles classification) were randomly assigned to one of three groups (omeprazole 10 mg or 20 mg, or placebo) once daily for 4 weeks."	5.13	Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. ( Chiba, T; Chikama, T; Inokuchi, H; Kawamura, S; Murakami, A; Serizawa, H; Tanabe, S; Tsuru, T; Uemura, N; Umezu, T; Urata, T; Yamamoto, M; Yamauchi, M; Yoshida, T; Yurino, N, 2008)
"Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment."	5.11	Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005)
"Heartburn-dominant uninvestigated dyspepsia patients from 46 primary care centres were randomized to one of two active treatment strategies: omeprazole 20 mg daily (proton pump inhibitor-start) or ranitidine 150 mg bid (H2-receptor antagonist-start) for the first 4-8 weeks, stepping up to omeprazole 40 or 20 mg daily, respectively, for 4-8 weeks for persistent symptoms."	5.11	Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study. ( Armstrong, D; Barkun, AN; Chakraborty, B; Chiba, N; Sinclair, P; Smyth, S; Thomson, AB; Veldhuyzen van Zanten, SJ; White, RJ, 2005)
"To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux."	5.11	Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005)
"To investigate the efficacy of famotidine and omeprazole in the treatment of gastro-oesophageal reflux disease, especially non-erosive gastro-oesophageal reflux disease."	5.11	Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease. ( Fujita, F; Itoh, K; Itoh, M; Joh, T; Kataoka, H; Kubota, E; Mori, Y; Nakao, H; Ogasawara, N; Ohara, H; Oshima, T; Sasaki, M; Sobue, S; Tanida, S; Togawa, S; Wada, T; Yamada, T, 2005)
" Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily."	5.10	Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003)
"Data were pooled on patients (n = 826) with a diagnosis of functional dyspepsia from two placebo-controlled trials who were treated with omeprazole, 10 or 20 mg once daily, for 4 weeks."	5.10	Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? ( Bolling-Sternevald, E; Glise, H; Junghard, O; Lauritsen, K; Talley, NJ, 2003)
"Rabeprazole may be more effective than omeprazole and lansoprazole for the rapid relief of heartburn symptoms in patients with reflux esophagitis."	5.10	Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. ( Adachi, K; Fujishiro, H; Hamamoto, N; Hashimoto, T; Hattori, S; Hirakawa, K; Kaji, T; Katsube, T; Kinoshita, Y; Komazawa, Y; Mihara, T; Miyake, T; Niigaki, M; Ono, M; Shizuku, T; Suetsugu, H; Taniura, H; Yagi, J; Yamamoto, S, 2003)
" In 16 subjects with chronic heartburn, 24-hr gastric and esophageal pH were measured at baseline and again after six days of 20 mg omeprazole alone at 08:00 hr followed by placebo, 75 mg ranitidine, or 20 mg omeprazole at 22:00 hr."	5.10	Control of nocturnal gastric acidity: a role for low dose bedtime ranitidine to supplement daily omeprazole. ( Ciociola, AA; Filinto, J; Gardner, JD; Miner, PB; Robinson, M; Rodriguez-Stanley, S; Zubaidi, S, 2002)
"The 'Future of Acid Suppression Therapy' (FAST) trial evaluated, in actual clinical practice, the timing of symptom relief, changes in symptom severity, health-related quality of life and safety in endoscopically confirmed erosive gastro-oesophageal reflux disease treated with rabeprazole."	5.10	Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. ( Fitzgerald, S; Hegedus, R; Jokubaitis, L; Murthy, A; Robinson, M, 2002)
"To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)."	5.10	Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002)
"Rabeprazole has a faster onset of antisecretory action than omeprazole, and it is of interest to determine whether this translates into faster symptom relief in patients with gastro-oesophageal reflux disease."	5.10	A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. ( Blum, AL; Bytzer, P; Holtmann, G; Loeffler, V; Metz, M, 2002)
"Oesophageal pH and heartburn severity were determined in 27 GERD subjects at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way crossover fashion."	5.10	Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003)
"05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo."	5.09	Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000)
"The objective of this study was to compare the efficacy and safety of the proton pump inhibitor rabeprazole to that of the histamine-2 (H2)-receptor antagonist ranitidine in the treatment of erosive gastroesophageal reflux disease."	5.09	Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group. ( Farley, A; Humphries, TJ; Wruble, LD, 2000)
"This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis."	5.09	Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001)
"Our objective was to compare four management strategies for heartburn: therapy with an H2-receptor antagonist (ranitidine), therapy with a proton pump inhibitor (lansoprazole), crossover from ranitidine to lansoprazole ("step-up" therapy), and crossover from lansoprazole to ranitidine ("step-down" therapy)."	5.09	Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. ( Freston, JW; Henning, JM; Howden, CW; Huang, B; Lukasik, N, 2001)
"In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0."	5.09	Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. ( Crouch, SL; Jones, R, 1999)
"214 patients with symptomatic, non-erosive GERD (moderate to severe daytime and/or night-time heartburn greater than half the days over the past 6 months and during the 7- to 10-day pre-treatment period) were randomized to either lansoprazole 15 mg or lansoprazole 30 mg, or placebo o."	5.09	Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. ( Fisher, R; Greski-Rose, PA; Huang section sign, B; Kovacs, TO; Richter, JE, 1999)
"Because improvement in quality of life (QoL) is an important therapeutic goal in patients with heartburn but without esophagitis, the aim of the present study was to compare the impact of omeprazole 20 mg or 10 mg daily with that of placebo on QoL in patients with heartburn as the predominant symptom."	5.09	Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A; Wiklund, I, 1999)
"To compare the effects and tolerability of omeprazole and cisapride with that of placebo for control of heartburn in primary care patients."	5.09	Heartburn treatment in primary care: randomised, double blind study for 8 weeks. ( Bernklev, T; Berstad, A; Hatlebakk, JG; Hyggen, A; Madsen, PH; Mowinckel, P; Schulz, T; Walle, PO, 1999)
"Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study."	5.08	Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997)
" This study assessed 20 mg omeprazole daily (OM20), 10 mg omeprazole daily (OM10), and 150 mg ranitidine (RAN) twice daily for symptom relief in gastro-oesophageal reflux disease (GORD)."	5.08	Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. ( Hole, J; Newland, RD; Patel, AC; Turbitt, ML; Venables, TL; Wilcock, C, 1997)
"Patients with heartburn, without endoscopic signs of oesophagitis, were randomized to double-blind treatment with omeprazole, 20 or 10 mg once daily, or placebo, for 4 weeks (n = 509)."	5.08	Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. ( Anker-Hansen, O; Carlsson, R; Glise, H; Havelund, T; Hernqvist, H; Junghard, O; Lauritsen, K; Lind, T; Lundell, L; Pedersen, SA; Stubberöd, A, 1997)
"To examine dyspepsia symptom relief over 16 weeks and compare an omeprazole clinical management strategy with a commonly used combination of antacid-alginate followed by H2-antagonist."	5.08	The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected]. ( Evans, WM; Mason, I; Millar, LJ; Sheikh, RR; Taylor, MD; Todd, PL; Turbitt, ML, 1998)
"Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality."	5.08	Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997)
" is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis."	5.08	Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998)
"In our study omeprazole was superior to either lansoprazole or pantoprazole in the maintenance treatment of complicated gastro-oesophageal reflux disease."	5.08	A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. ( Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H, 1998)
" Eighty-eight patients with healed erosive/ulcerative oesophagitis and relief of heartburn after pre-treatment with omeprazole received maintenance treatment."	5.08	Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease. ( Aalykke, C; Havelund, T; Rasmussen, L, 1997)
"To define the optimum doses of omeprazole appropriate for acute and long-term therapy of patients with gastro-oesophageal reflux disease, 24-h oesophageal pH was measured in 12 patients with symptomatic reflux and an abnormal 24-h oesophageal acid exposure time (greater than 6%) in a randomized, double-blind, four-way crossover study comparing the effects of omeprazole 10, 20, or 40 mg/day and placebo."	5.07	Effect of different doses of omeprazole on 24-hour oesophageal acid exposure in patients with gastro-oesophageal reflux. ( Allen, ML; Bradstreet, TE; Cagliola, AJ; Humphries, TJ; Maton, PN; McIntosh, D; Robinson, M, 1991)
"The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief."	4.95	Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017)
"To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis."	4.82	Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004)
"Patients who had heartburn twice a week or more were treated with 20 mg omeprazole (OPZ) once daily for 8 wk as an initial therapy (study 1)."	3.77	Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. ( Fujiwara, A; Ishioka, H; Kawahara, Y; Nasu, J; Okada, H; Takenaka, R; Tsuzuki, T; Yamamoto, K; Yoshinaga, F, 2011)
" Patients were assessed for complete relief of heartburn (absence of symptoms in the preceding 7 days) after 4 weeks' treatment (omeprazole 10 or 20 mg once daily; ranitidine 150 mg twice daily)."	3.73	Psychological factors as a predictor of treatment response in patients with heartburn: a pooled analysis of clinical trials. ( Carlsson, J; Carlsson, R; Glise, H; Wiklund, I, 2006)
"To report a case of chronic, persistent cough induced by omeprazole therapy."	3.72	Omeprazole-induced intractable cough. ( Delafosse, C; Howaizi, M, 2003)
"A 3-month observational study was conducted in an OTC setting to determine whether consumers could (1) correctly self-select to use omeprazole for frequent heartburn, (2) comply with a product label that calls for 14 consecutive days of once-daily dosing, and (3) use more than 14 doses of medication only under the advice of a physician."	3.72	Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. ( Allgood, G; Allgood, L; Fendrick, AM; Grender, J; Peura, D; Schachtel, B; Shaw, M, 2004)
"Heartburn was controlled on lansoprazole 30 mg/per day in 76."	3.72	Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003)
"To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease."	3.71	Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002)
"We analysed baseline and follow-up assessments of heartburn symptoms and HRQL scores from three clinical trials (total n=1351) comparing omeprazole and ranitidine for acute symptomatic treatment of GERD."	3.70	Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. ( Crawley, JA; Joelsson, BO; Levine, DS; Revicki, DA; Zodet, MW, 1999)
" A further evaluation was undertaken in patients with symptoms suggestive of GERD and in patients with non-ulcer dyspepsia, to identify factors that might predict symptom relief during treatment with omeprazole."	3.70	The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. ( Bolling-Sternevald, E; Carlsson, R; Dent, J; Johnsson, F; Junghard, O; Lauritsen, K; Lundell, L; Riley, S, 1998)
"Empiric omeprazole therapy is a reasonable, initial approach to patients with suspected gastroesophageal reflux-related posterior laryngitis."	3.69	Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. ( Delgaudio, JM; Grist, WJ; Gussack, G; Waring, JP; Wo, JM, 1997)
"The burden of gastroesophageal reflux disease (GERD) is increasing in the Asia area and the majority of GERD patients have non-erosive reflux disease (NERD)."	2.78	Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease. ( Chang, JJ; Chen, LW; Chen, TH; Chiu, CT; Hsu, CM; Lin, CJ; Su, MY; Sung, CM; Wang, CC, 2013)
"pylori) eradication on gastroesophageal reflux disease is controversial."	2.71	The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. ( Güliter, S; Kandilci, U, 2004)
"In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0."	2.71	Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004)
" These data suggest that administration of a PPI before the evening meal maximizes acid control and would be the preferred dosing schedule in GERD patients, particularly those with nocturnal symptoms."	2.71	Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. ( McCallum, RW; Olyaee, M; Pehlivanov, ND; Sarosiek, I, 2003)
"Esomeprazole 40 mg is an effective and safe drug at least comparable to omeprazole in treating Chinese EE patients."	2.71	Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis. ( Chang, FY; Chen, CY; Lai, YL; Lee, SD; Lu, CL; Luo, JC, 2005)
"Management costs for gastroesophageal reflux disease are high because of the expensive medications used for maintenance therapy."	2.71	Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. ( Bernard, L; Fendrick, AM; Inadomi, JM; McIntyre, L, 2003)
"Esomeprazole 40 mg was also significantly more effective than omeprazole for healing at week 4 and for all secondary variables evaluating heartburn resolution."	2.69	Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. ( Collins, DW; D'Amico, D; Falk, GW; Hamelin, B; Joelsson, B; Johnson, DA; Kahrilas, PJ; Schmitt, C; Whipple, J, 2000)
"Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0."	2.68	Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997)
"Omeprazole is a highly effective treatment for peptic esophagitis."	2.66	Healing and relapse of severe peptic esophagitis after treatment with omeprazole. ( Beveridge, BR; Dent, J; Gibson, GG; Hetzel, DJ; Laurence, BH; Mackinnon, M; McCarthy, JH; Mitchell, B; Narielvala, FM; Reed, WD, 1988)
"Unexplained chest pain is potentially attributable to gastro-oesophageal reflux disease (GORD) or oesophageal motility disorders."	2.47	Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011)
"The consequences of nocturnal gastroesophageal reflux disease (GERD) may be greater than daytime GERD in terms of clinical complications such as increased risk of esophageal lesions and respiratory conditions, as well as issues of health-related quality of life, sleep, work productivity, and economics."	2.44	Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. ( Johnson, DA; Katz, PO, 2008)
"Whether these patients are part of the GERD spectrum or have another diagnosis is not clear."	2.43	Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. ( DeVault, KR, 2006)
"Gastroesophageal reflux disease (GERD) is defined as 'Chronic symptoms or mucosal damage produced by the abnormal reflux of gastric contents into the esophagus'."	2.42	[Significance of PPI-test in the diagnosis of GERD]. ( Ichimura, H; Kuwayama, H; Nishiki, R; Takada, H; Takahashi, M, 2004)
"Heartburn and other symptoms of gastroesophageal reflux disease can be a lifelong problem, affecting millions of Americans each year."	2.40	A practical approach to heartburn. ( Castell, DO, 1999)
"Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60."	1.72	Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022)
"Eight patients (17%) with relapse of dysphagia were referred to laparoscopic Heller myotomy with no surgical complication."	1.36	Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results. ( Dolina, J; Hep, A; Kroupa, R; Matyasova, Z; Mrazova, J; Novotny, I; Prokesova, J; Sedmik, J; Valek, V, 2010)
"Duodenal ulcer (DU) and gastroesophageal reflux disease (GERD) are often combined."	1.34	[Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease]. ( Tsimmerman, IaS; Vologzhanina, LG, 2007)
"Gastro-oesophageal reflux disease is one of the most common diseases in primary care and has a significant negative impact on patients' quality of life."	1.33	Validation of the Reflux Disease Questionnaire for a German population. ( Kulig, M; Leodolter, A; Malfertheiner, P; Nocon, M; Willich, SN, 2005)
"Severity and frequency of gastroesophageal reflux disease (GERD) related symptoms are associated with impaired health-related quality of life (HRQL)."	1.32	Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. ( Crawley, JA; Joshua-Gotlib, S; Levine, D; Revicki, DA; Zodet, MW, 2003)
"Patients with gastro-oesophageal reflux disease (GORD) frequently report that meals high in fat worsen heartburn."	1.31	Duodenal fat intensifies the perception of heartburn. ( Elashoff, JD; Fass, R; Lembo, A; Mayer, EA; Meyer, JH, 2001)
"Strategies to prevent Barrett's-related esophageal cancer have focused on reversal of Barrett's using pharmacological or surgical antireflux therapies and endoscopically-induced injury."	1.31	Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression? ( Fennerty, MB, 2002)
"Idiopathic hoarseness as a single symptom increases the odds ratio for laryngopharyngeal reflux disease 85 times."	1.31	[Typical and atypical symptoms of laryngopharyngeal reflux disease]. ( Jonaitis, L; Pribuisiene, R; Uloza, V, 2002)
"Only surgery improved regurgitation."	1.30	The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. ( Gadenstaetter, M; Glaser, K; Hinder, RA; Profanter, C; Wetscher, GJ, 1999)
"Gastroesophageal reflux may be responsible for atypical symptoms such as chronic cough and hoarseness."	1.29	Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy. ( Hunter, J; Katz, E; Lacayo, L; Suwak, B; Waring, JP, 1995)

Research

Studies (132)

Authors

Clinical Trials (12)

Trial Overview

Trial Outcomes

Number of Enrolled Participants With Achalasia

Number of Enrolled Participants With Active Ulceration of the Stomach and/or Duodenum.

Number of Enrolled Participants With Anxiety and/or Depression

Number of Enrolled Participants With Aperistalsis

Number of Enrolled Participants With Belching Disorders

Number of Enrolled Participants With Candida Esophagitis.

Number of Enrolled Participants With Chronic Idiopathic Nausea

Number of Enrolled Participants With Cyclic Vomiting Syndrome

Number of Enrolled Participants With Distal Esophageal Spasm

Number of Enrolled Participants With Eosinophilic Esophagitis

Number of Enrolled Participants With Esophageal Ulceration.

Number of Enrolled Participants With Functional Bloating

Number of Enrolled Participants With Functional Chest Pain of Presumed Esophageal Origin

Number of Enrolled Participants With Functional Diarrhea

Number of Enrolled Participants With Functional Dysphagia

Number of Enrolled Participants With Functional Gallbladder Disorder

Number of Enrolled Participants With Functional Heartburn

Number of Enrolled Participants With Functional Vomiting

Number of Enrolled Participants With Gastric Outlet Obstruction

Number of Enrolled Participants With Globus

Number of Enrolled Participants With Hypertensive Peristalsis

Number of Enrolled Participants With Ineffective Esophageal Motility

Number of Enrolled Participants With Irritable Bowel Syndrome

Number of Enrolled Participants With Jackhammer Esophagus

Number of Enrolled Participants With Neoplasm of the Esophagus, Stomach or Duodenum

Number of Enrolled Participants With Nutcracker Esophagus

Number of Enrolled Participants With Rapid Contraction

Number of Enrolled Participants With Reflux Esophagus.

Number of Enrolled Participants With Unspecified Functional Bowel Disorder

Number of Enrolled Participants With Weak Peristalsis I

Number of Enrolled Participants With Weak Peristalsis II

Number of Participants Achieving at Least a 50% Improvement in the Gastroesophageal Reflux Disease Health-related Quality of Life Index (GERD-HRQL) From Baseline to 12 Months

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.76)	18.7374
1990's	30 (22.73)	18.2507
2000's	78 (59.09)	29.6817
2010's	19 (14.39)	24.3611
2020's	4 (3.03)	2.80

Authors	Studies
Vaezi, MF	1
Brunton, S	1
Mark Fendrick, A	1
Howden, CW	3
Atkinson, C	1
Pelletier, C	1
Jacob, R	1
Spechler, SJ	2
Barberio, B	1
Visaggi, P	1
Savarino, E	2
de Bortoli, N	1
Black, CJ	1
Ford, AC	1
Corazziari, ES	1
Gasbarrini, A	1
D'Alba, L	1
D'Ovidio, V	1
Riggio, O	1
Passaretti, S	1
Annibale, B	1
Cicala, M	1
Repici, A	1
Bassotti, G	1
Ciacci, C	1
Di Sabatino, A	1
Neri, M	1
Bragazzi, MC	1
Ribichini, E	1
Radocchia, G	1
Iovino, P	1
Marazzato, M	1
Schippa, S	1
Badiali, D	1
Hunter, JG	1
Jones, KM	1
Lee, R	1
Smith, BR	1
Mashimo, H	1
Sanchez, VM	1
Dunbar, KB	1
Pham, TH	1
Murthy, UK	1
Kim, T	1
Jackson, CS	1
Wallen, JM	1
von Rosenvinge, EC	1
Pearl, JP	1
Laine, L	1
Kim, AW	1
Kaz, AM	1
Tatum, RP	1
Gellad, ZF	1
Lagoo-Deenadayalan, S	1
Rubenstein, JH	1
Ghaferi, AA	1
Lo, WK	1
Fernando, RS	1
Chan, BS	1
Paski, SC	1
Provenzale, D	1
Castell, DO	2
Lieberman, D	1
Souza, RF	1
Chey, WD	1
Warren, SR	1
Davis-Karim, A	1
Melton, SD	1
Genta, RM	1
Serpi, T	1
Biswas, K	1
Huang, GD	1
Thélin, CS	1
Richter, JE	4
Li, MJ	1
Li, Q	1
Sun, M	1
Liu, LQ	1
Waghray, A	1
Waghray, N	1
Perzynski, AT	1
Votruba, M	1
Wolfe, MM	1
Kim, JH	1
Lee, YC	1
Kim, EH	1
Park, JC	1
Shin, SK	1
Lee, SK	1
Jung, DH	1
Park, JJ	1
Youn, YH	1
Park, H	1
Beales, ILP	1
Chiu, CT	1
Hsu, CM	1
Wang, CC	1
Chang, JJ	1
Sung, CM	1
Lin, CJ	1
Chen, LW	1
Su, MY	1
Chen, TH	1
Ostovaneh, MR	1
Saeidi, B	1
Hajifathalian, K	1
Farrokhi-Khajeh-Pasha, Y	1
Fotouhi, A	1
Mirbagheri, SS	1
Emami, H	1
Barzin, G	1
Mirbagheri, SA	1
Walker, D	1
Ng Kwet Shing, R	1
Jones, D	1
Gruss, HJ	1
Reguła, J	1
Toseef, MU	1
Saeed, A	1
Mohi-Ud-Din, E	1
Usmanghani, K	1
Nazar, H	1
Nawaz, A	1
Ahmad, I	1
Siddiqui, FA	1
Johnson, DA	2
Katz, PO	1
Uemura, N	1
Inokuchi, H	1
Serizawa, H	1
Chikama, T	1
Yamauchi, M	1
Tsuru, T	1
Umezu, T	1
Urata, T	1
Yurino, N	1
Tanabe, S	1
Yoshida, T	1
Kawamura, S	1
Murakami, A	1
Yamamoto, M	1
Chiba, T	1
Zheng, RN	1
McColl, KE	1
Gillen, D	1
Kroupa, R	1
Hep, A	1
Dolina, J	1
Valek, V	1
Matyasova, Z	1
Prokesova, J	1
Mrazova, J	1
Sedmik, J	1
Novotny, I	1
de Leone, A	2
Tonini, M	1
Dominici, P	2
Grossi, E	2
Pace, F	3
Riegler, G	1
Tsuzuki, T	1
Okada, H	1
Kawahara, Y	1
Takenaka, R	1
Nasu, J	1
Ishioka, H	1
Fujiwara, A	1
Yoshinaga, F	1
Yamamoto, K	1
Kahrilas, PJ	4
Hughes, N	1
Manabe, N	1
Haruma, K	1
Ito, M	1
Takahashi, N	1
Takasugi, H	1
Wada, Y	1
Nakata, H	1
Katoh, T	1
Miyamoto, M	1
Tanaka, S	1
Ndraha, S	1
Robb-Nicholson, C	2
Reimer, C	1
Bytzer, P	3
Talley, NJ	3
Moore, MG	1
Sprogis, A	1
Katelaris, P	1
Pribuisiene, R	1
Uloza, V	1
Jonaitis, L	1
Fennerty, MB	1
Bolling-Sternevald, E	2
Lauritsen, K	4
Junghard, O	6
Glise, H	4
Laheij, RJ	1
Van Rossum, LG	1
Jansen, JB	1
Verheugt, FW	1
Gardner, JD	2
Sloan, S	1
Robinson, M	6
Miner, PB	2
Paré, P	1
Armstrong, D	2
Pericak, D	1
Pyzyk, M	1
Inadomi, JM	1
McIntyre, L	1
Bernard, L	1
Fendrick, AM	2
Howaizi, M	1
Delafosse, C	1
Pehlivanov, ND	1
Olyaee, M	1
Sarosiek, I	1
McCallum, RW	1
Revicki, DA	2
Zodet, MW	2
Joshua-Gotlib, S	1
Levine, D	1
Crawley, JA	2
Füessl, HS	1
Vakil, N	1
Orr, WC	1
Abu Farsakh, N	1
Adachi, K	1
Hashimoto, T	1
Hamamoto, N	1
Hirakawa, K	1
Niigaki, M	1
Miyake, T	1
Taniura, H	1
Ono, M	1
Kaji, T	1
Suetsugu, H	1
Yagi, J	1
Komazawa, Y	1
Mihara, T	1
Katsube, T	1
Fujishiro, H	1
Shizuku, T	1
Hattori, S	1
Yamamoto, S	1
Kinoshita, Y	1
Carlsson, R	5
Lind, T	3
Shaw, M	1
Schachtel, B	1
Allgood, L	1
Allgood, G	1
Grender, J	1
Peura, D	1
Blum, A	1
De Herdt, D	1
Dubois, D	1
Takahashi, M	1
Nishiki, R	1
Ichimura, H	1
Takada, H	1
Kuwayama, H	1
Juul-Hansen, P	1
Rydning, A	2
Güliter, S	1
Kandilci, U	1
Dent, J	3
Rajabally, YA	1
Jacob, S	1
Bochenek, WJ	1
Mack, ME	1
Fraga, PD	1
Metz, DC	1
Madan, K	1
Ahuja, V	1
Kashyap, PC	1
Sharma, MP	1
Nocon, M	1
Kulig, M	1
Leodolter, A	1
Malfertheiner, P	1
Willich, SN	1
Calabrese, C	1
Bortolotti, M	1
Fabbri, A	1
Areni, A	1
Cenacchi, G	1
Scialpi, C	1
Miglioli, M	1
Di Febo, G	1
Calleja, JL	1
Suarez, M	1
De Tejada, AH	1
Navarro, A	1
Allgood, LD	1
Grender, JM	1
Shaw, MJ	1
Peura, DA	1
Taghavi, SA	1
Ghasedi, M	1
Saberi-Firoozi, M	1
Alizadeh-Naeeni, M	1
Bagheri-Lankarani, K	1
Kaviani, MJ	1
Hamidpour, L	1
Veldhuyzen van Zanten, SJ	1
Barkun, AN	1
Chiba, N	1
Thomson, AB	1
Smyth, S	1
Sinclair, P	1
Chakraborty, B	1
White, RJ	1
Ott, EA	1
Mazzoleni, LE	1
Edelweiss, MI	1
Sander, GB	1
Wortmann, AC	1
Theil, AL	1
Somm, G	1
Cartell, A	1
Rivero, LF	1
Uchôa, DM	1
Francesconi, CF	1
Prolla, JC	1
Zentilin, P	1
Accornero, L	1
Dulbecco, P	1
Savarino, V	1
Chen, CY	1
Lu, CL	1
Luo, JC	1
Chang, FY	1
Lee, SD	1
Lai, YL	1
Inamori, M	1
Togawa, J	1
Iwasaki, T	1
Ozawa, Y	1
Kikuchi, T	1
Muramatsu, K	1
Chiguchi, G	1
Matsumoto, S	1
Kawamura, H	1
Abe, Y	1
Kirikoshi, H	1
Kobayashi, N	1
Shimamura, T	1
Kubota, K	1
Sakaguchi, T	1
Saito, S	1
Ueno, N	1
Nakajima, A	1
Tsuji, S	1
Kawano, S	1
Wada, T	1
Sasaki, M	1
Kataoka, H	1
Tanida, S	1
Itoh, K	1
Ogasawara, N	1
Oshima, T	1
Togawa, S	1
Kubota, E	1
Yamada, T	1
Mori, Y	1
Fujita, F	1
Ohara, H	1
Nakao, H	1
Sobue, S	1
Joh, T	1
Itoh, M	1
Annese, V	1
Prada, A	1
Zambelli, A	1
Casalini, S	1
Nardini, P	1
Bianchi Porro, G	1
Mine, S	1
Iida, T	1
Tabata, T	1
Kishikawa, H	1
Tanaka, Y	1
Bigard, MA	1
Genestin, E	1
DeVault, KR	1
Wiklund, I	2
Carlsson, J	1
Dohmen, W	1
Fuchs, W	1
Anandasabapathy, S	1
Jaffin, BW	1
Tsimmerman, IaS	1
Vologzhanina, LG	1
Halling, K	1
Umeda, N	1
Miki, K	1
Hoshino, E	1
Collen, MJ	1
Strong, RM	1
Waring, JP	2
Lacayo, L	1
Hunter, J	1
Katz, E	1
Suwak, B	1
Shoenut, JP	1
Wieler, JA	1
Micflikier, AB	1
Loizeau, E	1
Decktor, DL	1
Maton, PN	2
Sabesin, S	2
Roufail, W	1
Kogut, D	1
Roberts, W	1
McCullough, A	1
Pardoll, P	1
Saco, L	1
Sontag, SJ	2
Kogut, DG	1
Fleischmann, R	1
Campbell, DR	2
Richter, J	1
McFarland, M	1
Lehman, GA	1
Castell, D	1
Havelund, T	3
Aalykke, C	1
Rasmussen, L	1
Bate, CM	2
Green, JR	2
Axon, AT	2
Murray, FE	1
Tildesley, G	2
Emmas, CE	1
Taylor, MD	3
Galmiche, JP	1
Barthelemy, P	1
Hamelin, B	2
Venables, TL	1
Newland, RD	1
Patel, AC	1
Hole, J	1
Wilcock, C	1
Turbitt, ML	2
Anker-Hansen, O	2
Hernqvist, H	2
Lundell, L	3
Pedersen, SA	2
Stubberöd, A	2
Parks, SM	1
Wo, JM	1
Grist, WJ	1
Gussack, G	1
Delgaudio, JM	1
Katz, P	1
Mason, I	1
Millar, LJ	1
Sheikh, RR	1
Evans, WM	1
Todd, PL	1
Murrays, FE	1
Owen, SM	1
Emmas, C	1
Jaspersen, D	1
Diehl, KL	1
Schoeppner, H	1
Geyer, P	1
Martens, E	1
Johnsson, F	1
Riley, S	1
Jones, R	1
Crouch, SL	1
Wetscher, GJ	1
Glaser, K	1
Gadenstaetter, M	1
Profanter, C	1
Hinder, RA	2
Kovacs, TO	2
Greski-Rose, PA	1
Huang section sign, B	1
Fisher, R	1
Johnston, BT	1
Hatlebakk, JG	2
Hyggen, A	1
Madsen, PH	1
Walle, PO	1
Schulz, T	1
Mowinckel, P	1
Bernklev, T	1
Berstad, A	2
Wilhelmsen, I	1
Olafsson, S	1
Levine, DS	1
Joelsson, BO	1
Vernet Vernet, M	1
Roca Figueras, G	1
Jovell Fernández, E	1
Iglesias Rodríguez, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
CSP #573 - A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors[NCT01265550]	Phase 3	366 participants (Actual)	Interventional	2012-08-13	Completed
Evaluation of the National Randomized Proton Pump Inhibitor De-prescribing (RaPPID) Program[NCT03719170]		208,266 participants (Actual)	Interventional	2019-09-16	Completed
Prospective Study Assessing Patient Satisfaction of Symptom Control With Proton Pump Inhibitor Dosing Regimen[NCT02623816]	Phase 4	64 participants (Actual)	Interventional	2014-08-31	Completed
A Multi-center, Double-blind, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Sodium Alginate Oral Suspension (50 mg/ml) in Comparison to Omeprazole (20 mg/Cap) to Treat Non-erosive Gastro-esophageal Reflux Disease (NERD)[NCT01338077]	Phase 3	195 participants (Actual)	Interventional	2010-10-31	Completed
Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial[NCT01269788]	Phase 2/Phase 3	144 participants (Actual)	Interventional	2010-08-31	Completed
A Phase III, Multi-centre, Double-blind, Double-dummy, Randomised, Study to Assess the Superiority of Zegerid® 20 mg vs. Losec® 20 mg in the Rapid Relief of Heartburn Associated With GERD as on Demand Therapy[NCT01493089]	Phase 3	239 participants (Actual)	Interventional	2011-04-30	Completed
Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466]	Phase 4	82 participants (Actual)	Interventional	2019-05-26	Terminated (stopped due to Budget for the study was withdrawn and discontinued)
Economic Impact of Guidelines for Gastroesophageal Reflux Disease[NCT00057174]		484 participants (Anticipated)	Interventional		Completed
"Double-Blind Placebo-Controlled Randomized Withdrawal Trial Assessing the Efficacy and Tolerability of On-Demand Maintenance Therapy With 10mg o.d. Rabeprazole for 6 Months in Non-Erosive Reflux Disease Patients With Complete Symptom Relief After 4 Week [NCT00236392]	Phase 3	422 participants (Actual)	Interventional	2001-10-31	Completed
Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534]	Phase 3	407 participants (Actual)	Interventional	2006-10-31	Completed
Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908]	Phase 1	32 participants (Actual)	Interventional	2006-09-30	Completed
Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555]	Phase 2	450 participants	Interventional	2006-02-28	Suspended
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	Participants (Count of Participants)
All Enrolled	2

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	125

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	130

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	51

Intervention	Participants (Count of Participants)
All Enrolled	86

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	16

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	8

Intervention	Participants (Count of Participants)
All Enrolled	13

Intervention	Participants (Count of Participants)
All Enrolled	4

Intervention	Participants (Count of Participants)
All Enrolled	7

Intervention	Participants (Count of Participants)
All Enrolled	1

Intervention	Participants (Count of Participants)
All Enrolled	221

Intervention	Participants (Count of Participants)
All Enrolled	32

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	3

Intervention	Participants (Count of Participants)
All Enrolled	1

Intervention	Participants (Count of Participants)
All Enrolled	152

Intervention	Participants (Count of Participants)
All Enrolled	8

Intervention	Participants (Count of Participants)
All Enrolled	0

Intervention	Participants (Count of Participants)
All Enrolled	2

Intervention	Participants (Count of Participants)
All Enrolled	2

Intervention	Participants (Count of Participants)
All Enrolled	4

Intervention	Participants (Count of Participants)
All Enrolled	56

Intervention	Participants (Count of Participants)
All Enrolled	10

Intervention	Participants (Count of Participants)
All Enrolled	9

"Success; ≥50% improvement in the baseline GERD-HRQL score at 12 months.~Failure; <50% improvement in the baseline GERD-HRQL score at 12 months or:~For patients randomized to Surgical Treatment: a.<50% improvement in the baseline GERD-HRQL score and/or persistent heartburn of sufficient severity to warrant treatment with any antisecretory medication, antireflux medication or neurotropic medication at any quarterly clinic visit.~For patients randomized to Active Medical or Placebo Medical Treatment:~a.inability to tolerate both study medications or b.For patients treated with desipramine, i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with the second drug at any quarterly clinic visit. c.For patients in whom desipramine is contraindicated,i.<50% improvement in baseline GERD-HRQL score symptom after at least 10 weeks of treatment with baclofen or its corresponding placebo at any quarterly clinic visit." (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Anxiety and/or Depression.

Intervention	Participants (Count of Participants)
Medical Treatment Group	7
Surgical Treatment Group	18
Placebo Medical Treatment Group	3

Association between anxiety and/or depression (GAD-7 and PHQ-9) and the outcome of medical and surgical treatments (success or failure) will be evaluated. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Belching Disorders

Intervention	Participants (Count of Participants)
Medical Treatment Group	2
Surgical Treatment Group	5
Placebo Medical Treatment Group	0

Presence of belching disorders as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Chronic Idiopathic Nausea

Intervention	Participants (Count of Participants)
Medical Treatment Group	3
Surgical Treatment Group	12
Placebo Medical Treatment Group	2

Presence of chronic idiopathic nausea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Cyclic Vomiting Syndrome

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	3
Placebo Medical Treatment Group	0

Presence of cyclic vomiting syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Bloating

Intervention	Participants (Count of Participants)
Medical Treatment Group	1
Surgical Treatment Group	7
Placebo Medical Treatment Group	1

Presence of functional bloating as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Chest Pain of Presumed Esophageal Origin

Intervention	Participants (Count of Participants)
Medical Treatment Group	1
Surgical Treatment Group	1
Placebo Medical Treatment Group	0

Presence of functional chest pain of presumed esophageal origin as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Diarrhea

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional diarrhea as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Dysphagia

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional dysphagia as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Gallbladder Disorder

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional gallbladder disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Heartburn

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of functional heartburn as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Functional Vomiting

Intervention	Participants (Count of Participants)
Medical Treatment Group	7
Surgical Treatment Group	14
Placebo Medical Treatment Group	3

Presence of functional vomiting as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Globus

Intervention	Participants (Count of Participants)
Medical Treatment Group	1
Surgical Treatment Group	1
Placebo Medical Treatment Group	1

Presence of globus as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Irritable Bowel Syndrome

Intervention	Participants (Count of Participants)
Medical Treatment Group	0
Surgical Treatment Group	0
Placebo Medical Treatment Group	0

Presence of irritable bowel syndrome as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Participants With Unspecified Functional Bowel Disorder

Intervention	Participants (Count of Participants)
Medical Treatment Group	3
Surgical Treatment Group	10
Placebo Medical Treatment Group	3

Presence of unspecified functional bowel disorder as assessed by the ROME III functional GI disorders questionnaire. (NCT01265550)
Timeframe: 12 months

Number of Successful Surgery Participants With Closure of the Crura With Non-absorbable Suture to be Snug With a Dilator of at Least 56 French Diameter Performed.

Number of Successful Surgery Participants With Complete Mobilization of the Fundus, to Include All Short Gastric and Posterior Gastric Vessels to the Base of the Left Crus Performed.

Number of Successful Surgery Participants With Dissection of Distal Esophagus to Obtain at Least 2.5cm of Tension-free, Intra-abdominal Esophagus Performed.

Number of Successful Surgery Participants With Fundoplication Between 1.5 and 2.5cm in Length Performed.

Number of Successful Surgery Participants With Fundoplication Floppiness Demonstrated by Passing a Grasper Between Fundoplication and Dilator-filled Esophagus Performed.

Number of Successful Surgery Participants With Fundoplication Placed Above the Epiphrenic Fat Pad, Using 3 Sutures Performed.

Number of Successful Surgery Participants With Fundoplication Secured to Esophagus With at Least Two Sutures Performed.

Number of Successful Surgery Participants With Passage of an Esophageal Dilator of at Least 56 French Diameter Performed.

Symptom Frequency and Severity/Distress Scores From Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) (Overall)

Intervention	Participants (Count of Participants)
Medical Treatment Group	2
Surgical Treatment Group	5
Placebo Medical Treatment Group	0

"The 15-symptom GSAS questionnaire includes measures of: Gastrointestinal distress, Regurgitation/heartburn and Upper respiratory manifestations. The outcome measures were the number, frequency, and severity of GSAS symptoms reported at 6 weeks. Measures were based on aggregate GSAS scores. Symptom numbers range from 0 to 15. Frequency is based on the total number of reported days of symptomatic episodes in the past week divided by the number of potential symptoms (number reported divided by 15 for GSAS score. The range for frequency score:0 to 7 with higher scores indicative of greater frequency of symptoms. Severity is the average distress score reported by individuals (zero if no symptoms). Symptom distress is based on a 4 point Likert scale (0= not at all, 1=somewhat, 2=quite a bit and 3=very much). The higher the score the worse outcome.~." (NCT02623816)
Timeframe: 6 weeks

Determination of Median Time to Sustained Partial Response as Defined by Reduction in Likert Severity Scale Used to Assess Pain Associated With Heartburn in the Patient

Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: up to 14 days following treatment

Median Time to Sustained Partial Response

Reduction in severity of heartburn by 2 points or more on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: up to 14 days

Median Time to Sustained Total Relief

Time to sustained total relief, defined as zero severity (no heartburn) on a 9-point Likert severity scale, which is sustained for 45 minutes or more (NCT01493089)
Timeframe: 14 days

Percentage of Patients Responding in 45 Minutes

percentage of patients who have achieved sustained partial response, sustained response, or sustained total relief, by 45 minutes (NCT01493089)
Timeframe: up to 14 days

Percentage of Patients Responding in 60 Minutes

Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 60 minutes (NCT01493089)
Timeframe: 14 days

Percentage of Patients Responding in 90 Minutes

Proportion of patients who have achieved sustained response, sustained partial response or sustained total relief by 90 minutes (NCT01493089)
Timeframe: 14 days

Intervention	score on a scale (Mean)
	GSAS Symptoms Score	GSAS Frequency Score	GSAS Severity Score
Optimal Dosing	5.2	1.0	0.6
Sub-optimal Dosing	8.5	2.2	1.0

Intervention	Minutes (Median)
Zegerid Group	37.5
Losec Group	37.5

Intervention	Minutes (Median)
Zegerid Group	37.5
Losec Group	37.5

Intervention	Minutes (Median)
Zegerid Group	105.0
Losec Group	105.0

Intervention	percentage of patients (Number)
Zegerid Group	65
Losec Group	62.2

Article	Year
Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis. Neurogastroenterology and motility, 2023, Volume: 35, Issue:1 Topics: Adult; Alginates; Dexlansoprazole; Endoscopy, Gastrointestinal; Gastroesophageal Reflux; Gastrointes	2023
Review article: the management of heartburn during pregnancy and lactation. Alimentary pharmacology & therapeutics, 2020, Volume: 51, Issue:4 Topics: Alginates; Antacids; Breast Feeding; Contraindications, Drug; Female; Gastroesophageal Reflux; Gastr	2020
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. Medicine, 2017, Volume: 96, Issue:39 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole;	2017
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. Reviews in gastroenterological disorders, 2008,Spring, Volume: 8, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; O	2008
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. Gut, 2011, Volume: 60, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn;	2011
Epigastric pain in dyspepsia and reflux disease. Reviews in gastroenterological disorders, 2003, Volume: 3 Suppl 4 Topics: Abdominal Pain; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspepsia; Gastroesophageal Reflux; He	2003
Sleep issues in gastroesophageal reflux disease: beyond simple heartburn control. Reviews in gastroenterological disorders, 2003, Volume: 3 Suppl 4 Topics: Antacids; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitor	2003
[Significance of PPI-test in the diagnosis of GERD]. Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:8 Topics: Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors	2004
Clinical strategies -- interactive case discussions. Alimentary pharmacology & therapeutics, 2004, Volume: 20 Suppl 5 Topics: Anti-Ulcer Agents; Barrett Esophagus; Female; Heartburn; Humans; Male; Middle Aged; Omeprazole	2004
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. Alimentary pharmacology & therapeutics, 2004, Nov-15, Volume: 20, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D	2004
Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Alimentary pharmacology & therapeutics, 2006, Volume: 23 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Endoscopy, Digestive Sys	2006
A practical approach to heartburn. Hospital practice (1995), 1999, Nov-15, Volume: 34, Issue:12 Topics: Anti-Ulcer Agents; Circadian Rhythm; Drug Administration Schedule; Drug Therapy, Combination; Female	1999

Article	Year
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. BMJ open gastroenterology, 2022, Volume: 9, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph	2022
Successful Treatment of Refractory Lymphocytic Esophagitis With Vedolizumab. The American journal of gastroenterology, 2019, Volume: 114, Issue:9 Topics: Adult; Antibodies, Monoclonal, Humanized; Budesonide; Deglutition Disorders; Endoscopy, Digestive Sy	2019
Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat. Gastroenterology, 2009, Volume: 137, Issue:1 Topics: Drug Administration Schedule; Dyspepsia; Evidence-Based Medicine; Gastric Acid; Gastric Mucosa; Gast	2009
Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2010, Volume: 23, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Botulinum Toxins, Type A; Catheterization; Cohort Studies; Combined	2010
If I take the blood thinner Plavix, should I avoid using Prilosec or other heartburn medications? Mayo Clinic women's healthsource, 2010, Volume: 14, Issue:5 Topics: Anti-Ulcer Agents; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Health Knowledge, Atti	2010
Proton pump inhibitor step-down therapy for GERD: a multi-center study in Japan. World journal of gastroenterology, 2011, Mar-21, Volume: 17, Issue:11 Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Drug Administration Schedul	2011
Ask the doctor. I recently switched from Prilosec to its generic form omeprazole, and it doesn't relieve my heartburn as well as Prilosec. Aren't generics supposed to be the same as the brand-name drugs? Harvard women's health watch, 2012, Volume: 19, Issue:8 Topics: Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drugs, Generic; Heartburn; Humans; Omeprazole;	2012
[Adverse events associated with long-term use of proton pump inhibitors]. Ugeskrift for laeger, 2012, Sep-24, Volume: 174, Issue:39 Topics: Anti-Ulcer Agents; Bacterial Infections; Congenital Abnormalities; Dyspepsia; Fractures, Bone; Gastr	2012
[Typical and atypical symptoms of laryngopharyngeal reflux disease]. Medicina (Kaunas, Lithuania), 2002, Volume: 38, Issue:7 Topics: Adult; Anti-Ulcer Agents; Diagnosis, Differential; Esophagus; Female; Gastroesophageal Reflux; Heart	2002
Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression? Reviews in gastroenterological disorders, 2002, Volume: 2 Suppl 2 Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors;	2002
Over-the-counter omeprazole (prilosec OTC). The Medical letter on drugs and therapeutics, 2003, Aug-04, Volume: 45, Issue:1162 Topics: Enzyme Inhibitors; H(+)-K(+)-Exchanging ATPase; Heartburn; Humans; Nonprescription Drugs; Omeprazole	2003
Omeprazole-induced intractable cough. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:11 Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Cough; Female; Heartburn; Humans; Omeprazole	2003
Health-related quality of life improves with treatment-related GERD symptom resolution after adjusting for baseline severity. Health and quality of life outcomes, 2003, Nov-29, Volume: 1 Topics: Adult; Anti-Ulcer Agents; Clinical Trials as Topic; Data Interpretation, Statistical; Female; Gastro	2003
[Heartburn without esophagitis. Symptoms more important than the finding?]. MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39 Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul	2003
Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. Journal of gastroenterology, 2003, Volume: 38, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Gastrointestinal; Esophagitis; Female; He	2003
[The proton pump especially steady in grip. Fast help for nightly reflux complaints]. MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Heartburn; Humans; Omepr	2003
Self-selection and use patterns of over-the-counter omeprazole for frequent heartburn. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004, Volume: 2, Issue:1 Topics: Adolescent; Adult; Anti-Ulcer Agents; Anticonvulsants; Consumer Product Safety; Drug Labeling; Femal	2004
[When sour does not make merry at all . Fast relief for patients with reflux]. MMW Fortschritte der Medizin, 2003, Apr-10, Volume: 145, Issue:15 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr	2003
Second opinion. I have tried the new over-the-counter drug Prilosec for my heartburn, and it was very helpful. The package says I should take it for only two weeks and that if my heartburn comes back after that, I should see my doctor. If Prilosec helps, Mayo Clinic health letter (English ed.), 2004, Volume: 22, Issue:7 Topics: Anti-Ulcer Agents; Heartburn; Humans; Omeprazole; Time Factors	2004
One on one. I often have heartburn. Is it safe to use Prilosec OTC long term? Mayo Clinic women's healthsource, 2004, Volume: 8, Issue:8 Topics: Heartburn; Humans; Omeprazole	2004
Neuropathy associated with lansoprazole treatment. Muscle & nerve, 2005, Volume: 31, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Heartburn; Humans; Lansop	2005
Validation of the Reflux Disease Questionnaire for a German population. European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:2 Topics: Adult; Aged; Anti-Ulcer Agents; Cross-Cultural Comparison; Dyspepsia; Female; Gastroesophageal Reflu	2005
Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. The American journal of gastroenterology, 2005, Volume: 100, Issue:3 Topics: Adult; Biopsy; Epithelial Cells; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Ma	2005
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole. Digestive diseases and sciences, 2005, Volume: 50, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa	2005
Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut, 2005, Volume: 54, Issue:8 Topics: Adult; Drug Administration Schedule; Female; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Io	2005
Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aerophagy; Anti-Ulcer Agents; Benzimidazoles; Dose-R	2005
A new-generation H2 receptor antagonist: quicker and stronger acid inhibition than proton pump inhibitors in the clinical setting? Journal of gastroenterology, 2005, Volume: 40, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Benzimidazoles; Gastric Acid; Gastric Acidity D	2005
Psychological factors as a predictor of treatment response in patients with heartburn: a pooled analysis of clinical trials. Scandinavian journal of gastroenterology, 2006, Volume: 41, Issue:3 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Anxiety; Child; Child, Preschool; Endoscopy, Gastrointes	2006
Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy. The Annals of otology, rhinology, and laryngology, 2006, Volume: 115, Issue:8 Topics: Adult; Aged; Case-Control Studies; Deglutition Disorders; Electric Impedance; Enzyme Inhibitors; Eso	2006
[Characteristics of a combined course of duodenal ulcer and gastroesophageal reflux disease]. Klinicheskaia meditsina, 2007, Volume: 85, Issue:3 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antidepressive Agents, Second-Generation; Cla	2007
Responsiveness of measures of heartburn improvement in non-erosive reflux disease. Health and quality of life outcomes, 2007, Jun-11, Volume: 5 Topics: Adult; Aged; Esophageal pH Monitoring; Female; Gastroesophageal Reflux; Heartburn; Humans; Male; Mid	2007
Treatment of pyrosis does not insure adequate control of gastric acid reflux. The American journal of gastroenterology, 1995, Volume: 90, Issue:4 Topics: Barrett Esophagus; Chronic Disease; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Hydroge	1995
Chronic cough and hoarseness in patients with severe gastroesophageal reflux disease. Diagnosis and response to therapy. Digestive diseases and sciences, 1995, Volume: 40, Issue:5 Topics: Case-Control Studies; Chronic Disease; Cough; Female; Fundoplication; Gastroesophageal Reflux; Heart	1995
The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole. Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:5 Topics: Adult; Aged; Deglutition Disorders; Dose-Response Relationship, Drug; Esophagus; Female; Gastroesoph	1993
[Retrosternal pain. Clinical conference about a subject with esophagitis]. Revue medicale de la Suisse romande, 1993, Volume: 113, Issue:7 Topics: Esophagitis, Peptic; Esophagoscopy; Female; Gastroesophageal Reflux; Heartburn; Humans; Manometry; M	1993
Omeprazole maintenance therapy for GERD. The Journal of family practice, 1997, Volume: 45, Issue:4 Topics: Adult; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Double-Blind Method; Gastroesophageal	1997
Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Topics: Anti-Ulcer Agents; Cough; Deglutition Disorders; Female; Follow-Up Studies; Gastroesophageal Reflux;	1997
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scandinavian journal of gastroenterology, 1998, Volume: 33, Issue:10 Topics: Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Esophagitis, Peptic; Gastric Acidity Dete	1998
The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. American journal of surgery, 1999, Volume: 177, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cisapride;	1999
Gastroesophageal reflux disease and a HAPPI quality of life. The American journal of gastroenterology, 1999, Volume: 94, Issue:7 Topics: Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors; Quality of Life	1999
By the way, doctor. I take 10 mg of Prilosec about four times each week to control my heartburn. Does taking this drug on a continuing basis affect my body's ability to utilize nutrients in food? Harvard women's health watch, 1999, Volume: 7, Issue:3 Topics: Anti-Ulcer Agents; Digestion; Heartburn; Humans; Intestinal Absorption; Omeprazole	1999
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:12 Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M	1999
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:12 Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M	1999
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:12 Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M	1999
Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:12 Topics: Anti-Ulcer Agents; Double-Blind Method; Female; Heartburn; Histamine H2 Antagonists; Humans; Male; M	1999
[Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians]. Atencion primaria, 2000, Mar-15, Volume: 25, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Drug	2000
Heartburn treatment in primary care. Prescribing omeprazole would conflict with desire to control prescribing costs. BMJ (Clinical research ed.), 2000, May-20, Volume: 320, Issue:7246 Topics: Anti-Ulcer Agents; Costs and Cost Analysis; Drug Administration Schedule; Heartburn; Humans; Omepraz	2000
Heartburn treatment in primary care. Step up approach to management is best. BMJ (Clinical research ed.), 2000, May-20, Volume: 320, Issue:7246 Topics: Antacids; Anti-Ulcer Agents; Costs and Cost Analysis; Heartburn; Humans; Omeprazole	2000
Heartburn treatment in primary care. Study's results seem to be promotional rather than evidence based. BMJ (Clinical research ed.), 2000, May-20, Volume: 320, Issue:7246 Topics: Advertising; Anti-Ulcer Agents; Costs and Cost Analysis; Heartburn; Humans; Omeprazole	2000
[Heartburn. Only a harmless symptom?]. MMW Fortschritte der Medizin, 2001, Mar-08, Volume: 143, Issue:10 Topics: Esophagitis, Peptic; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitors	2001
Treatment of gastroesophageal reflux disease: to step or not to step. The American journal of gastroenterology, 2001, Volume: 96, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Hist	2001
Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms. Digestive diseases and sciences, 2001, Volume: 46, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Formularies as Topic; Gastroesophageal Reflux; Heal	2001
Clinical and ethical concerns about switching patient treatment to "therapeutically interchangeable" medications. Archives of internal medicine, 2001, Sep-24, Volume: 161, Issue:17 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Pathways; Esophagitis, Peptic; Ethics, Medical; He	2001
Duodenal fat intensifies the perception of heartburn. Gut, 2001, Volume: 49, Issue:5 Topics: Adult; Aged; Analysis of Variance; Anti-Ulcer Agents; Dietary Fats; Dose-Response Relationship, Drug	2001
What is the best pharmacologic approach to managing moderate to severe heartburn? The Journal of family practice, 2001, Volume: 50, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Double-Blind Method; Female; Heartburn; Histamine H2	2001
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002, Volume: 34, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit	2002
Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2002, Volume: 34, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Fundop	2002

omeprazole and Pyrosis